Syracuse

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Archive ouverte

Prévost, Jérémie | Gasser, Romain | Beaudoin-Bussières, Guillaume | Richard, Jonathan | Duerr, Ralf | Laumaea, Annemarie | Anand, Sai Priya | Goyette, Guillaume | Benlarbi, Mehdi | Ding, Shilei | Medjahed, Halima | Lewin, Antoine | Perreault, Josée | Tremblay, Tony | Gendron-Lepage, Gabrielle | Gauthier, Nicolas | Carrier, Marc | Marcoux, Diane | Piché, Alain | Lavoie, Myriam | Benoit, Alexandre | Loungnarath, Vilayvong | Brochu, Gino | Haddad, Elie | Stacey, Hannah | Miller, Matthew | Desforges, Marc | Talbot, Pierre | Maule, Graham | Côté, Marceline | Therrien, Christian | Serhir, Bouchra | Bazin, Renée | Roger, Michel | Finzi, Andrés

Edité par CCSD ; Cell Press -

International audience. SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion